Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody

Curr Opin Mol Ther. 2007 Apr;9(2):190-6.


Micromet Inc, in collaboration with Merck Serono SA, is developing adecatumumab for the potential treatment of adenocarcinomas, including breast and prostate cancer. Adecatunmumab is a fully human antibody targeting epithelial cell adhesion molecule (EpCAM). Adecatumumab is currently undergoing phase II clinical trials in breast and prostate cancer.

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antigens, Neoplasm / immunology*
  • Cell Adhesion Molecules / immunology*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Drug Evaluation, Preclinical*
  • Epithelial Cell Adhesion Molecule
  • Humans
  • Patents as Topic
  • Protein Engineering / methods*
  • Structure-Activity Relationship


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, Neoplasm
  • Cell Adhesion Molecules
  • EPCAM protein, human
  • Epithelial Cell Adhesion Molecule
  • adecatumumab